Acute Kidney Injury (AKI)
Auxora™ has the potential to prevent and to treat acute kidney injury, also known as acute renal failure. In the severe and critical COVID-19 pneumonia trial (CARDEA), we saw a 40% reduction in reported AKI in Auxora-treated patients as compared to placebo-treated patients. AKI is a common consequence of severe COVID-19 pneumonia.
Acute Kidney Injury
AKI is marked by three distinct phases; the initial injury, the
recovery from that injury and then the long-term damage
resulting from the initial injury. Patients who experience AKI
are at risk for long-term damage and may develop chronic
kidney disease and end-stage renal failure.
There are no approved therapeutics for AKI.
Auxora™: Solving the Unmet
Need for Patients with Acute
Kidney Injury
patients are hospitalized each year
of these patients have stage 2 or stage 3 (moderate to severe) AKI
- Chronic kidney disease
- End-stage renal failure leading to death
Auxora™: Solving the
Unmet Need for Patients
with Acute Kidney Injury
We are currently conducting preclinical studies of Auxora in
an AKI animal model. Initial results from these studies have
shown that the glomerular filtration rate (GFR – a standard
measure of kidney function) in animals treated with Auxora™
is approximately 61% higher at 24 hours after injury than in
animals treated with placebo (p=0.04).
Auxora™ has the potential for:
• Greater recovery of renal function
• Reduced need for dialysis
• Reduced risk of mortality
• Prevention of progression to chronic kidney disease
Early Treatment with Auxora™ May Offer Significant Benefits to Acute Kidney Injury Patients and Prevent Kidney Disease Progression
